WARCEF-STAT and WARCEF-CLIN are two highly coordinated units which together constitute WARCEF, a two-arm (1:1) double-blind randomized multicenter clinical trial. Its primary aim is to test the primary null hypothesis of no difference between warfarin (INR 2.5-3, target 2.75) and aspirin (325 mg/day) therapies in time to the first to occur of death from any cause, ischemic stroke, or symptomatic non-fatal intracerebral hemorrhage (ICH) among patients with low (<35%) cardiac Left Ventricular Ejection Fraction (LVEF). The main secondary aim is to test the hypothesis of no difference in these therapies in time to the first to occur of death, ischemic stroke, ICH, myocardial infarction (Ml) or heart failure (HF) hospitalization. The operational goals of WARCEF-STAT remain as stated for the first cycle: 1) to conduct, efficiently integrate, and be responsible for all WARCEF data management, double-blinding, medication management, quality control, and reporting operations. 2) to specify, conduct and be responsible for all interim, safety, and final statistical analyses for WARCEF and for the reporting of these results. 3) to transmit to the Clinical Coordinating Center (CCC) in a timely fashion all of the data which the WARCEF-CLIN principal investigator needs to meet his responsibilities in terms of ensuring patient safety and directing all clinical operations. Extensive changes required by expansion to Europe in 2002 have provided the Statistical Analysis Center (SAC) with a much simpler and more efficient organizational structure than at trial start;equipped the trial with a powerful and highly cost-effective, secure, web-based data management system that is uniform across all countries and continents;and greatly improved its data quality and reporting capabilities. The statistical design is retained, with a straightforward extension to address possible continent-by-treatment interactions. The design is powerful. It compares two active medications with a symmetrical two-tailed test. Any of the three possible efficacy outcomes would be clinically important: If warfarin is better, use warfarin. If aspirin is better, use aspirin. If evidence is insufficient to declare either better, use aspirin given its lower cost and easier administration. The trial is thus expected to be clinically decisive if it is completed with satisfactory power. 3201 patients with 2-6 years of follow-up are required for 80% power for the primary aim. As of 8/01/06, 1,242 have been recruited in North America and Europe. Although major efforts to increase recruitment there are under way, given past performance these two continents alone are not likely to reach the goal. Expansion to India is therefore proposed in detail, and shown to be attainable and cost-effective.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZNS1-SRB-K (46))
Program Officer
Moy, Claudia S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
Biostatistics & Other Math Sci
Schools of Public Health
New York
United States
Zip Code
Di Tullio, Marco R; Qian, Min; Thompson, John L P et al. (2018) Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment. ESC Heart Fail 5:800-808
Lee, Tetz C; Qian, Min; Lip, Gregory Y H et al. (2018) Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial). Am J Cardiol 122:821-827
Teerlink, John R; Qian, Min; Bello, Natalie A et al. (2017) Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients: From the WARCEF Trial. JACC Heart Fail 5:603-610
Nakanishi, Koki; Di Tullio, Marco R; Qian, Min et al. (2017) Resting Heart Rate and Ischemic Stroke in Patients with Heart Failure. Cerebrovasc Dis 44:43-50
Kato, Tomoko S; Di Tullio, Marco R; Qian, Min et al. (2016) Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure?- Subanalysis of the WARCEF Trial. Circ J 80:619-26
Ye, Siqin; Qian, Min; Zhao, Bo et al. (2016) CHA2 DS2 -VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. Eur J Heart Fail 18:1261-1266
Di Tullio, Marco R; Qian, Min; Thompson, John L P et al. (2016) Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial. Stroke 47:2031-7
Ye, Siqin; Cheng, Bin; Lip, Gregory Y H et al. (2015) Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. Am J Cardiol 116:904-12
Homma, Shunichi; Thompson, John L P; Qian, Min et al. (2015) Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy. Circ Heart Fail 8:504-9
Shaffer, Jonathan A; Thompson, John L P; Cheng, Bin et al. (2014) Association of quality of life with anticoagulant control in patients with heart failure: the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial. Int J Cardiol 177:715-7

Showing the most recent 10 out of 17 publications